Nutrabiotech CA77.1 CAS 2412270-22-3, brain penetrant chaperone-mediated autophagy CMA activator compound

CMA Activator CA77.1 CAS 2412270-22-3

CA77.1, also known as N‑(4‑(6‑chloroquinoxalin‑2‑yl)phenyl)acetamide, CAS No 2412270‑22‑3, is an orally‑active, brain‑penetrant chaperone‑mediated autophagy (CMA) activator derived from AR‑7 analogue.
Our high‑purity ≥99% CA77.1 raw powder up‑regulates lysosomal LAMP2A receptor, triggers CMA pathway and accelerates misfolded‑tau protein degradation. Widely applied in Alzheimer’s‑disease, neuronal proteostasis and autophagy‑related laboratory research. Strictly for scientific‑research use only, we supply 1mg‑100mg customizable laboratory‑grade packages with cold‑chain shipping support.

Category: Tags: , ,
CA77.1 (CAS 2412270-22-3) CMA Activator | Chaperone-Mediated Autophagy, LAMP2A, Neurodegeneration

CA77.1 CAS 2412270-22-3
Chaperone-Mediated Autophagy Activator

An orally available, brain-penetrant small molecule that selectively activates chaperone-mediated autophagy (CMA) without affecting macroautophagy. First-in-class CMA activator demonstrating in vivo activity and improved pathology in Alzheimer's disease mouse models. A breakthrough tool compound for neurodegeneration, proteostasis, and aging research.

CMA Activator Brain-Penetrant Orally Available In Vivo Active LAMP2A Pathway Neuroprotective Proteostasis
Request a Quote Technical Specs
297.74
MW (C16H12ClN3O)
≥98%
Purity (HPLC)
CMA-Selective
No Macroautophagy Effect

Molecular Information

Name: CA77.1
CAS: 2412270-22-3
Formula: C16H12ClN3O
MW: 297.74 g/mol
SMILES: Clc1cc2ncc(nc2cc1)
  c3ccc(cc3)NC(=O)C
InChIKey: ZQXMPDVGBWOTBY
  -UHFFFAOYSA-N
LogP: 2.7
tPSA: 54.9
Appearance: White to off-white powder
Synonyms: CA / N-[4-(6-Chloro-2-
  quinoxalinyl)phenyl]acetamide
Storage: -20°C (powder), 2-8°C short term
🧪
CAS Number
2412270-22-3
⚖️
Molecular Weight
297.74
🎯
Primary Activity
CMA Activator
✅
Purity
≥98%

Product Technical Specifications

Complete physicochemical properties and QC parameters for CA77.1 (CAS 2412270-22-3)

📋 Physicochemical Properties

  • Product NameCA77.1
  • IUPAC NameN-(4-(6-Chloroquinoxalin-2-yl)phenyl)acetamide
  • CAS Number2412270-22-3
  • SynonymsCA; N-[4-(6-Chloro-2-quinoxalinyl)phenyl]acetamide
  • Molecular FormulaC16H12ClN3O
  • Molecular Weight297.74 g/mol
  • SMILESClc1cc2ncc(nc2cc1)c3ccc(cc3)NC(=O)C
  • InChIKeyZQXMPDVGBWOTBY-UHFFFAOYSA-N
  • LogP2.7
  • tPSA54.9
  • HBD / HBA1 / 3
  • Rotatable Bonds2
  • HS Code2934.99.9001

🔬 Quality Control & Handling

  • Purity (HPLC)≥98%
  • AppearanceWhite to off-white powder
  • SolubilityDMSO (~5 mg/mL); Ethanol (~1 mg/mL)
  • Storage Condition-20°C (powder); 2-8°C short term
  • Storage ClassCold storage required
  • HandlingHandle in fume hood; use appropriate PPE
  • QC DocumentationCOA / HPLC / NMR / MS / MSDS
  • Pack Sizes1g / 5g / 10g / 100g / 1KG
  • Stock StatusIn Stock
  • Use StatementResearch use only; not for human/clinical use

Key Molecular Targets & Pathway Profile

CA77.1 acts selectively on the chaperone-mediated autophagy (CMA) machinery, distinguishing it from macroautophagy modulators

🧬 LAMP2A Receptor 🔬 Hsc70 Chaperone ♻️ CMA Pathway 🧠 Lysosomal Degradation ⚡ KFERQ Motif Substrates 🛡️ Proteostasis ⚙️ Protein Aggregate Clearance 🧫 Selective Autophagy

How CA77.1 Works: Selective CMA Activation

CA77.1 activates the chaperone-mediated autophagy pathway without triggering macroautophagy, enabling precise study of selective protein degradation

1

CMA Pathway Upregulation

CA77.1 enhances the activity of the CMA machinery, increasing the rate at which cytosolic proteins bearing KFERQ-like motifs are recognized and targeted for lysosomal degradation via the LAMP2A receptor complex.

2

Selective Substrate Clearance

Hsc70 chaperone recognizes KFERQ-motif substrates and delivers them to the lysosomal membrane, where they are translocated through LAMP2A multimers for degradation. CA77.1 boosts this selective clearance of pathogenic and damaged proteins.

3

No Macroautophagy Activation

Unlike rapamycin or other autophagy inducers, CA77.1 does not affect macroautophagy (autophagosome-mediated bulk degradation). This selectivity allows researchers to isolate CMA-specific contributions to proteostasis and disease pathology.

Research Applications & Disease Models

CA77.1's selective CMA activation makes it a versatile tool across neurodegeneration, aging, and drug discovery research

🧠

Alzheimer's Disease

Improves pathology in Alzheimer's disease mouse models. CMA activation enhances clearance of pathogenic proteins via the LAMP2A/Hsc70 pathway, reducing toxic protein accumulation and neuronal damage associated with neurodegeneration.

AD Mouse Models
🧬

Neurodegeneration (PD / HD)

Parkinson's and Huntington's disease research benefits from CMA-mediated clearance of misfolded protein aggregates (α-synuclein, mutant huntingtin). CA77.1 enables selective upregulation of this degradation pathway in neuronal models.

Protein Aggregates
♻️

Autophagy Research

A first-in-class tool for selectively activating CMA without macroautophagy interference. Enables dissection of CMA-specific vs. macroautophagy contributions to cellular proteostasis, a longstanding challenge in autophagy biology.

CMA-Selective
⏳

Aging & Longevity

CMA activity declines with age, contributing to proteostasis failure. CA77.1 enables investigation of whether restoring CMA function can counteract age-related protein aggregation and extend healthspan in aging models.

Proteostasis
🎗️

Cancer Biology

CMA plays a dual role in cancer — tumor-suppressive in some contexts and tumor-promoting in others. CA77.1 allows researchers to probe CMA's context-dependent functions in tumor cell metabolism, survival, and resistance mechanisms.

Oncology
💊

Drug Discovery Pipeline

As a first-in-class, orally available, brain-penetrant CMA activator, CA77.1 serves as a lead compound and chemical probe for neurodegenerative disease drug discovery programs targeting the autophagy-lysosome pathway.

First-in-Class

Key Literature & Landmark Publications

Seminal papers on CA77.1, chaperone-mediated autophagy activation, and neurodegenerative disease applications

Dong S, Wang Q, et al. CA77.1 is an orally available brain-penetrant CMA activator that improves pathology in Alzheimer's disease mouse models. Nature Communications.
CMA activator; in vivo neurodegeneration model
Kaushik S, Cuervo AM. Chaperone-mediated autophagy: a unique way to enter the lysosome world. Trends in Cell Biology. 2012;22(8):407-417.
doi: 10.1016/j.tcb.2012.05.003
Cuervo AM, Dice JF. A receptor for the selective uptake and degradation of proteins by lysosomes. Science. 1996;273(5274):501-503.
doi: 10.1126/science.273.5274.501
Schneider JL, Cuervo AM. Chaperone-mediated autophagy: dedicated savior and unlucky victim of aging. Autophagy. 2014;10(6):987-988.
doi: 10.4161/auto.28372
Bourdenx M, Martin SE, et al. Chaperone-mediated autophagy prevents collapse of the neuronal proteostasis network. Nature Neuroscience.
CMA in neurodegeneration; LAMP2A pathway
Koga H, Martinez-Vicente M, Macian F, et al. A photoconvertible fluorescent reporter to track chaperone-mediated autophagy. Nature Communications. 2011;2:386.
doi: 10.1038/ncomms1393

Available Sizes & Ordering

Research-grade CA77.1 (CAS 2412270-22-3) with full QC documentation; research packs and bulk custom quantities supported

TierPack SizeStock StatusSuitable ForLead Time
Standard1 gIn StockBiochemical / cell-based assaysSame/next-day ship
Medium5 gIn StockIn vivo pharmacology, long-term studiesSame/next-day ship
Large10 gIn StockMulti-lab collaborations, HTSSame/next-day ship
Bulk100 gIn StockProcess development, scale-upQuote to confirm
Industrial1 KGMade to orderPilot/production scale, CMO supplyBatch delivery

For exact pricing and availability please contact us for a quote. Bulk orders qualify for tiered discounts.

Frequently Asked Questions (FAQ)

What is CA77.1 (CAS 2412270-22-3), and what makes it unique?
CA77.1 is a synthetic small-molecule chaperone-mediated autophagy (CMA) activator (C16H12ClN3O, MW 297.74). It is orally available, brain-penetrant, and in vivo active, making it a first-in-class chemical tool for studying CMA in living organisms. Unlike rapamycin and other macroautophagy inducers, CA77.1 selectively activates CMA without affecting the macroautophagy pathway, enabling researchers to isolate CMA-specific contributions to proteostasis and disease.
How does CA77.1 differ from macroautophagy activators like rapamycin?
CA77.1 selectively activates chaperone-mediated autophagy (CMA), a lysosomal degradation pathway in which the Hsc70 chaperone recognizes KFERQ-like motif-bearing substrates and translocates them across the lysosomal membrane via the LAMP2A receptor. Unlike rapamycin and other macroautophagy inducers, CA77.1 does not affect macroautophagy (the bulk autophagy pathway involving autophagosome formation). This selectivity allows researchers to study CMA-specific contributions to proteostasis without confounding macroautophagy activation.
Does CA77.1 cross the blood-brain barrier?
Yes. CA77.1 is brain-penetrant and orally available, making it suitable for in vivo neurodegeneration studies. Its physicochemical properties (MW 297.74, LogP 2.7, tPSA 54.9, 2 rotatable bonds) are favorable for blood-brain barrier penetration. This enables investigation of CMA activation in the central nervous system, which is critical for Alzheimer's, Parkinson's, and Huntington's disease research.
How does CA77.1 improve Alzheimer's disease pathology?
CA77.1 enhances the clearance of pathogenic proteins via chaperone-mediated autophagy. In Alzheimer's disease mouse models, CMA activation promotes degradation of toxic protein species that accumulate in neurons. By upregulating the LAMP2A-dependent lysosomal degradation pathway, CA77.1 improves cellular proteostasis and reduces pathology associated with neurodegenerative protein aggregates, demonstrating therapeutic potential for neurodegeneration.
What in vivo dosing is recommended for CA77.1?
CA77.1 is orally bioavailable and has demonstrated in vivo activity in mouse models of neurodegeneration. Specific dosing regimens should be determined based on your experimental model and research objectives. As an orally active compound, it can be administered via oral gavage or in diet. Researchers should consult primary literature for model-specific dosing protocols. Contact us for formulation and handling guidance.
How should CA77.1 be dissolved for biological assays?
CA77.1 is soluble in DMSO (~5 mg/mL) and ethanol (~1 mg/mL). For cell-based assays, prepare a concentrated DMSO stock and dilute into aqueous media, keeping final DMSO concentration ≤0.1% v/v. For in vivo studies, DMSO-based formulations can be further diluted with appropriate vehicles (e.g., PEG300, saline). Stock solutions should be aliquoted and stored at -20°C, protected from light and moisture.
What is the LAMP2A pathway and why is it important?
LAMP2A (lysosome-associated membrane protein type 2A) is the rate-limiting receptor for chaperone-mediated autophagy. Cytosolic proteins bearing a KFERQ-like motif are recognized by the Hsc70 chaperone and delivered to the lysosomal surface, where they bind LAMP2A. LAMP2A monomers then multimerize to form a translocation complex that unfolds and internalizes the substrate for degradation. LAMP2A levels decline with age, contributing to reduced CMA activity in aging and neurodegeneration — making it a key therapeutic target.
Is QC documentation provided? Can I request a sample?
Every batch ships with a Certificate of Analysis (COA) including HPLC purity, NMR structural confirmation, and MS data. MSDS/SDS, solubility datasheets, and Certificates of Origin are available on request. Sample evaluation policy is available for qualified institutions — please contact us for details.

Need CA77.1 for Your Research?

Research-grade CA77.1 (CAS 2412270-22-3) — purity ≥98%, COA included
A first-in-class, brain-penetrant CMA activator — request a quote today

Request a Quote →

Related products